Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Economic evaluation of extended panel analysis in cancer patients with historical NHS diagnostic germline genetic testing - A modeling study based on real-world data.

European journal of medical genetics - 1 Dec 2024

Xi Qin, Patel Rahul, Linton-Willoughby Thomas, Short John, Tischkowitz Marc, Snape Katie, Morris Stephen

Abstract excerpt

BACKGROUND: The South West Thames Centre for Genomics implemented a wider diagnostic Next Generation Sequencing (NGS) gene panel for eligible cancer patients undergoing diagnostic testing whilst restricting data analysis and reporting for BRCA1/BRCA2/PALB2/CHEK2 1100delC only as per contemporaneous guidelines. This study investigated the cost-utility of reanalyzing existing diagnostic grade extended panel data...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA2 Protein
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Checkpoint Kinase 2

Share to Cost-Benefit Analysis

Share to Genetic Testing

Share to Germ-Line Mutation

Share to High-Throughput Nucleotide Sequencing

Share to Ovarian Neoplasms

Source

Identifiers

PMID: 39260602
DOI: 10.1016/j.ejmg.2024.104969

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Economic evaluation of extended panel analysis in cancer patients with historical NHS diagnostic germline genetic testing - A modeling study based on real-world data.PMID 39260602Read ↗

Routine germline genetic testing in 3552 unselected NHS breast cancer patients: Evidence informing testing criteria and implementation of a ‘BRCA-DIRECT’ mainstreaming pathwaySemantic proximity Read ↗

The clinical utility and costs of whole-genome sequencing to detect cancer susceptibility variants—a multi-site prospective cohort studySemantic proximity Read ↗

Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer.Semantic proximity Read ↗

Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States.Semantic proximity Read ↗

A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.Semantic proximity Read ↗

A cost analysis of a cancer genetic service model in the UKSemantic proximity Read ↗

A review of the cost-effectiveness of genetic testing for germline variants in familial cancerSemantic proximity Read ↗

Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French studySemantic proximity Read ↗

Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers.Semantic proximity Read ↗

Micro-costing Diagnostics in Oncology: From Single-Gene Testing to Whole Genome SequencingSemantic proximity Read ↗

Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patientsSemantic proximity Read ↗

Cost Comparison of Genetic Testing Strategies in Women With Epithelial Ovarian Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.